Newsletters
August 2023 Newsletter
August 24, 2023ToxTracker is a unique, stem-cell based assay which takes advantage of a Green Fluorescent Protein (GFP) reporter system to identify hazard and mode-of-action (MOA) of potentially genotoxic materials. On July 20th, IIVS was formally awarded ToxTracker Certification by Toxys, a Dutch Biotechnology company and the developers of the assay.
62nd Annual Meeting of the Society of Toxicology
March 14, 2023IIVS is looking forward to exhibiting at the 62nd Annual Meeting of the Society of Toxicology! If attending, please visit us during ToxExpo at booth #834.
March 2023 Newsletter
March 1, 2023IIVS is pleased to share that the PMI In Vitro Alternatives Laboratory in Neuchâtel, Switzerland is now GIVIMP certified. Good In Vitro Method Practices (GIVIMP) is an OECD guidance document that provides a framework for quality standards specific to in vitro laboratory operations.
IIVS Leadership Newsletter
February 3, 2023Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance of non-animal approaches worldwide.
November 2022 Newsletter
November 10, 2022IIVS is pleased to announce the appointment of Amanda Ulrey to our Board of Directors. As a 20-year veteran at IIVS, Mandy is currently Vice President of Business Operations and where she is primarily responsible for instituting quality management systems and regulatory compliance throughout the organization, as well as administering IIVS’ business-to-business certification in Good In Vitro Method Practices (GIVIMP).
What’s New at IIVS – Sept. 2022
September 14, 2022Dr. Dan Bagley joins the IIVS Board of Directors; President of IIVS Recognized with Award by PCRM; Award for IIVS Training on Alternative Methods IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series” focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the use of animal experimentation in Latin America.
May 2022 Newsletter
July 1, 2022The ability to ascertain the maximum limit of a compound that can be applied to the skin without inducing skin sensitization is a critical safety criterion for virtually any risk assessment. Using regression models developed by Givaudan (Kempthal, Switzerland), IIVS is able to perform a computational approach to determine predicted EC3 values (Effective Concentration required to induce a 3-fold upregulation of lymph node cell proliferation) using a combination of OECD approved assays (KeratinoSens, hCLAT, and kDPRA). This value can be used to assess risk for compounds to be included in formulations.
IIVS News and Updates June 2022
July 1, 2022NEW! Good In Vitro Method Practices (GIVMP) Certification IIVS is pleased to announce our new business-to-business GIVIMP Certification Program created to help laboratories: As an OECD guidance document, GIVIMP sets forth internationally recognized quality standards to help ensure that new in vitro methods are ready for implementation, and to foster confidence in the resulting data for use by industry or regulatory bodies.
IIVS e-News – December 2021
December 9, 2021In addition to IIVS’ non-animal safety testing services, we also provide efficacy testing designed to evaluate raw materials and formulations for anti-inflammatory and skin tone modulating properties. Inflammation is a common effect experienced after encounters with irritating substances, bacterial infection or by those suffering from auto-immune diseases.
IIVS e-News – September 2021
September 16, 2021It’s been a very exciting year in the field of New Approach Methodologies (NAMs) with the release of the OECD 497 and 498 Test Guidelines which have codified Defined Approaches for Skin Sensitization and the Reconstructed Human Epidermis Phototoxicity Test, respectively.